● Recruiting

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Condition: Marginal Zone Lymphoma · Sponsor: Henan Cancer Hospital

PhaseN/A

Planned participants30

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

This description comes directly from the study's public registry record.

Talk to the study team

Zhihua Yao, M.D. Ph.D · +8613592622292 · zlyyyaozhihua1260@zzu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Zhengzhou, Henan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07233720